Log in
Enquire now
‌

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT02769780
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT027697800
Health Conditions in Trial
Narcolepsy
Narcolepsy
0
Trial Recruitment Size
1,5000
Trial Sponsor
Jazz Pharmaceuticals
Jazz Pharmaceuticals
0
Trial Collaborator
‌
Narcolepsy Network
0
‌
Wake Up Narcolepsy
0
Clinical Trial Start Date
July 8, 2015
0
Primary Completion Date
August 9, 2021
0
Study Completion Date
August 9, 2021
0
Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Case-Only0
Observational Study Perspective
Prospective0
Participating Facility
Jazz Pharmaceuticals
Jazz Pharmaceuticals
0
Official Name
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy0
Last Updated
April 5, 2022
0
Study summary

Nexus is a collaboration between academic institutions, advocacy and industry to answer important questions about narcolepsy. It is a web-based observational study of patient-reported outcomes in adult patients with narcolepsy, with follow-up every six months. Nexus website: www.narcolepsyregistry.com

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.